← Back to Search

TSC Biosample Repository and Natural History Database

Cincinnati, OH
N/A
Recruiting
Research Sponsored by National Tuberous Sclerosis Association
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Diagnosis of tuberous sclerosis complex or lymphangioleiomyomatosis (sporadic LAM).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up average 15 years
Awards & highlights
No Placebo-Only Group

Summary

The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.

See full description
Eligible Conditions
  • Lymphangioleiomyomatosis
  • Tuberous Sclerosis Complex
  • Tuberous Sclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
* Diagnosis of tuberous sclerosis complex or lymphangioleiomyomatosis (sporadic LAM).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~average 15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and average 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Natural History data and biosamples including blood, tissue, or other types of biological samples from individuals with TSC

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Closest Location:Cincinnati Children's Hospital Medical Center· Cincinnati, OH

Who is running the clinical trial?

National Tuberous Sclerosis AssociationLead Sponsor
~3333 spots leftby Dec 2050